Roche confirms that its cobas MPXV test, as well as the LightMix research use only kits, detect the latest mpox virus variants
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
The partnership marks a significant milestone in integrating digital health education into medical curricula
He recently served as Senior Vice President of the API business at Shilpa Pharma Life Sciences for over 3 years
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
Morepen Labs successfully raised Rs. 200 Crore through QIP
The sales of medicines and other items sold through Jan Aushadhi Kendras have increased from Rs. 7.29 crore in 2014 to Rs. 1,470 crore by July 2024
Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
